Open Orphan PLC Exercise of Share Options (4587I)
14 Décembre 2020 - 8:30AM
UK Regulatory
TIDMORPH
RNS Number : 4587I
Open Orphan PLC
14 December 2020
Open Orphan plc
("Open Orphan" or the "Company")
Exercise of Share Options
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
pharmaceutical services CRO which is the world leader in the
testing of vaccines and antivirals using human challenge clinical
trials, announce s that following the exercise of share options by
a former hVIVO employee, application has been made to AIM for the
admission of 73,065 new ordinary shares of 0.1 pence each (the "New
Ordinary Shares"). Admission to trading on AIM of the New Ordinary
Shares ("Admission"), which will rank pari passu in all respects
with the Company's existing shares in issue, is expected to occur
on 17 December 2020.
Following Admission, the total number of ordinary shares with
voting rights in issue will be 668,052,261 and this figure may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the Financial Conduct Authority's Disclosure and Transparency
Rules.
For further information please contact
Open Orphan plc +353 (0)1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0)20 7614 5900
John Llewellyn-Lloyd / Benjamin Cryer
/ Dan Gee-Summons
finnCap plc (Joint Broker) +44 (0) 20 7220 500
Geoff Nash / James Thompson/ Richard
Chambers
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0)1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or openorphan@walbrookpr.com
Paul McManus / Alice Woodings +44 (0)7980 541 893 / +44 (0)7407
804 654
About Open Orphan ( www.openorphan.com )
Open Orphan is a rapidly growing niche CRO pharmaceutical
services company which is the world leader in the testing of
vaccines and antivirals through the use of human challenge clinical
trials. Conducted from Europe's only 24-bedroom quarantine clinic
with onsite virology providing individually isolated rooms and
connected to our specialist laboratory facility. hVIVO's challenge
studies require healthy volunteers to take part, volunteers are
recruited through FluCamp, learn more at www.FluCamp.com . The
hVIVO facility offers highly specialised virology and immunology
laboratory services to support pre-clinical and clinical
respiratory drug, antiviral, and vaccine discovery and development.
Reliable laboratory analysis underpinned by scientific expertise is
essential when processing and analysing clinical samples. Robust
quality processes support our team of scientists in the delivery of
submission ready data.
The Company has a leading portfolio of 8 viral challenge study
models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD
viral challenge models. As announced in early March, Open Orphan is
rapidly advancing a number of Coronavirus challenge study models
and expects to be helping many COVID-19 vaccine development
companies to test their vaccines. No other company in the world has
such a portfolio, with only two competitors globally having 1
challenge study model each. hVIVO also works with companies in the
UK and Ireland to provide COVID-19 testing to staff to protect
staff and customers from a workplace COVID-19 outbreak through its
COVID Clear offering.
Open Orphan comprises of two commercial specialist CRO services
businesses, hVIVO and Venn Life Sciences and is also building out a
valuable data platform business. hVIVO has built up one of the
world's largest databases of infectious disease progression data
and we are populating our Open Orphan Health Data platform with
this historical hVIVO data. In our clinical trials going forward,
we are also planning to collect data on volunteer's via wearables
during clinical trials. Therefore, Open Orphan's data, which may
yield valuable digital biomarkers, could be one of the more
sought-after datasets by many of the large wearables /smart watch
wearables providers around the world. In June 2019, Open Orphan
acquired AIM-listed Venn Life Sciences Holdings plc in a reverse
take-over and in January 2020 it completed the merger with hVIVO
plc in January 2020. Venn is an integrated drug development
consultancy firm which offers CMC (chemistry, manufacturing and
controls), preclinical, Phase I & II clinical trials design and
execution. The merger with hVIVO created a European full pharma
services company broadening the Company's customer base and with
complementary specialist CRO services, widened the range of the
Company's service offerings.
If you are interested in being contacted and provided with
details about future COVID-19 human challenge study research,
please leave your contact details at www.UKCovidChallenge.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ALSUASWRRBUUAAA
(END) Dow Jones Newswires
December 14, 2020 02:30 ET (07:30 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024